Pegylation for improving the effectiveness of therapeutic biomolecules

Drugs of Today

Volumn 45, Issue 9, 2009, Pages 687-695

  Pasut, Gianfranco ^a   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DEIMINASE; ASPARAGINASE MACROGOL; CALCITONIN; CATALASE; GLUCAGON LIKE PEPTIDE 1; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON BETA SERINE; INTERLEUKIN 6; LYSOSTAPHIN; METHIONINE GAMMA LYASE; PEGARGININE DEIMINASE; PEGCALCITONIN; PEGCATALASE; PEGGLUCAGON LIKE PEPTIDE 1; PEGGRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1B; PEGINTERLEUKIN 6; PEGLYSOSTAPHIN; PEGMETHIONINASE; PEGSUPEROXIDE DISMUTASE; PEGTRICHOSANTHIN; PEGTUMOR NECROSIS FACTOR ALPHA; PEGURICASE; SUPEROXIDE DISMUTASE; TRICHOSANTHIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE OXIDASE;

DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG RELEASE; IMMUNOGENICITY; LYMPHATIC LEUKEMIA; PEGYLATION; REVIEW;

CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; IMMUNOSUPPRESSION; MODELS, IMMUNOLOGICAL; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 75749158573     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.9.1416421     Document Type: Review

References (62)

1. Leader, B., Baca, Q.J., Golan, D.E. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discovery 2008, 7: 21-39.
2. Pinto Reis, C., Neufeld, R.J., Ribeiro, A.J., Veiga, F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006, 2(2): 53-65.
3. Almeida, A. J., Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007, 59(6): 478-90.
4. Martins, S., Sarmento, B., Ferreira, D.C., Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. Int J Nanomedicine 2007, 2(4): 595-607.
5. Tessmar, J.K., Göpferich, A.M. Matrices and scaffolds for protein delivery in tissue engineering. Adv Drug Deliv Rev 2007, 59(4-5): 274-91.
6. Jazayeri, J.A., Carroll, G.J. Fc-based cytokines: Prospects for engineering superior therapeutics. BioDrugs 2008, 22(1): 11-26.
7. Elliott, S., Lorenzini, T., Asher, S. et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003, 21(4): 414-21.
8. Jones, M.C., Patel, M. Insulin detemir: A long-acting insulin product. Am J Health Syst Pharm 2006, 63(24): 2466-72.
9. Veronese, F.M., Pasut G. PEGylation: Posttranslational bioengineering of protein biotherapeutics. Drug Discov Today Tech 2009 doi:10.1016/j.ddtec. 2009.02.002 (in press).
10. Maggon, K. R&D paradigm shift and billion-dollar biologics. In: Handbook of Pharmaceutical and Biotechnology. Gad, S.C. (Ed). Wiley: New York 2007, 161-98.
11. Bailon, P., Won, C.Y. PEG-modified biopharmaceuticals. Exper Opin Drug Deliv 2009, 6: 1-16.
12. Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M., Brayden, D.J. Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin Drug Deliv 2008, 5: 371-83.
13. Harris, J.M., Chess, R.B. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2(3): 214-21.
14. Veronese, F.M., Harris, J.M. (Eds.) Theme issues on PEGylation in Adv Drug Delivery Rev: "Peptide and Protein PEGylation" 2002, 54; "Peptide and Protein PEGytation II - Clinical Evaluation" 2003, 55; "Peptide and Protein Pegylation III" 2008, 60.
15. Manjula, B.N., Tsai, A., Updhya, R. et al. Site-specific PEGylation of hemoglobin at Cys-93(β): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Biocon Chem 2003, 14: 464-72.
16. Basu, A., Yang, K., Wang, M. et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006, 17(3): 618-30.
17. Israelachvili, J. The different faces of poly(ethylene glycol). Proc Natl Acad Sci USA 1997, 94(16): 8378-9.
18. Yang, K., Basu, A., Wang, M. et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003, 16(10): 761-70.
19. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J.M., Veronese, F.M. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995, 6(1): 62-9.
20. Kinstler, O.B., Brems, D.N., Lauren, S.L., Paige, A.G., Hamburger, J.B., Treuheit, M.J. Characterization and stability of N-terminally pegylated rhG-CSF. Pharm Res 1995, 13(7): 996-1002.
21. Guerra, P.L., Acklin, C., Kosky, A.A., Davis, J.M., Treuheit, M.J., Brems, D.N. PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor. Pharm Res 1998, 15(12): 1822-7.
22. De-Boer, R.H., Roskos, L.K., Cheung, E. et al. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans. Growth Factors 2000, 18(3): 215-26.
23. Kinstler, O., Moulinex, G., Treheit, M., Ladd, D., Gegg, C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Delivery Rev 2002, 54: 477-85.
24. Bailon, P., Palleroni, A., Schaffer, C.A. et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001, 12(2): 195-202.
25. Peginterferon alfa-2a Complete Product Information. Roche Pharmaceuticals: Nutley, NJ, USA.
26. Zwickl, C.M., Cocke, K.S., Tamura, R.N., Holzhausen, L.M., Brophy, G.T., Bick, P.H., Wierda, D. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam Appl Toxicol 1991, 16(2): 275-87.
27. Hermeling, S., Crommelin, D.J., Schellekens, H., Jiskoot, W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004, 21(6): 897-903.
28. Schellekens, H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008, 14: 191-202.
29. Filpula, D., Zhao, H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 2008, 60(1): 29-49.
30. Pasut, G., Sergi, M., Veronese, F.M. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008, 60(1): 69-78.
31. Wang, Y-S., Youngster, S., Grace, M., Bausch, J., Bordens, R., Wyss, D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002, 54(4): 547-70.
32. Pasut, G. PEGylated α interferons: Two different strategies to achieve increased efficacy. In: PEGylated Protein Drugs: Basic Science and Clinical Applications. Veronese, F.M. (Ed). Birkhäuser Verlag: Basel 2009, 205-16.
33. Greenwald, R.B., Yang, K., Zhao, H., Conover, C.D., Lee, S., Filpula, D. Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery system employing 1,6-elimination. Bioconjug Chem 2003, 14(2): 395-403.
34. Greenwald, R.B., Choe, Y.H., Conover, C.D., Shum, K., Wu, D., Royzen, M. Drug delivery systems based on trimethyl lock lactonization: Poly(ethylene glycol) prodrugs of amino-containing compounds. J Med Chem 2000, 43(3): 475-87.
35. Tsubery, H., Mironchik, M., Fridkin, M., Shechter. Y. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J Biol Chem 2004, 279(37): 38118-24.
36. Zhao, H., Yang, K., Martinez, A., Basu, A. et al. Linear and branched bicin linkers for releasable PEGylation of macromolecules: Controlled release in vivo and in vitro from mono-and multi-PEGylated proteins. Bioconjug Chem 2006, 17(2): 341-51.
37. Pasut, G., Caboi, F., Schrepfer, R.,Tonon, G., Schiavon, O., Veronese, F.M. New active poly(ethylene glycol) derivative for amino coupling. React Funct Polym 2007, 67: 529-39.
38. Pasut, G., Mero, A., Caboi, F., Scaramuzza, S., Sollai, L., Veronese, F.M. A new PEG-beta-alanine active derivative for releasable protein conjugation. Bioconjug Chem 2008, 19(12): 2427-31.
39. Veronese, F.M., Mero, A., Caboi, F., Sergi, M., Marongiu, C., Pasut, G. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem 2007, 18(6): 1824-30.
40. Rajan, R.S., Li, T., Aras, M. et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci 2006, 15(5): 1063-75.
41. Ganson, N.J., Kelly, S.J., Scarlett, E., Sundy, J.S., Hershfield, M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8(1): R12.
42. Armstrong, J. K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J., Garratty, G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110(1): 103-11.
43. Alden, C.L., Frith, C.H. Urinary system. In: Handbook of Toxicology Pathology. Haschek, W.M., Rousseaux, C.G. (Eds.). Academic Press: New York 1991, 339-41.
44. Fruijtier-Polloth, C. Safety assessment on polyethylene glycols (PEGs) and theirs derivatives as used in cosmetic products. Toxicology 2005, 214(1-2): 1-38.
45. Bendele, A., Seely, J., Richey, C., Sennello, G., Shopp, G. Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998, 42(2): 152-7.
46. Young, M.A., Malavalli, A., Winslow, N., Vandegriff, K.D., Winslow, R.M. Toxicity and hemodnamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Toxicol Sci 2007, 149: 333-42.
47. Shum, K.L., Leon, A., Viau, A.T., Pilon, D., Nucci, M., Shorr, R.G. The physiological and histopathological response of dogs to exchange transfusion with polyethylene glycol-modified bovine hemoglobin (PEG-Hb). Artif Cells Blood Substit Immobil Biotechnol 1996, 24(6): 655-83.
48. Conover, C., Lejunne, L., Linberg, R., Shum, K., Shorr, R.G. Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. Artif Cells Blood Substit Immobil Biotechnol 1996, 24(6): 599-611.
49. Wang, M., Basu, A., Palm, T. et al. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis. Bioconjug Chem 2006, 17(6): 1447-59.
50. Abuchowski, A., McCoy, J.R., Palczuk, N.C., van Es, T., Davis, F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977, 252(11): 3582-6.
51. Yang, Z., Wang, J., Lu, Q. et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 2004, 64(18): 6673-8.
52. Veronese, F.M., Caliceti, P., Pastorino, A., Schiavon, O., Sartore, L., Banci, L., Scolaro, L.M. Preparation, physicochemical and pharmacokinetic characterization of monomethoxypoly(ethylene glycol)-derivatized superoxide dismutase. J Contr Rel 1989, 10: 145-54.
53. Sundy, J.S., Ganson, N.J., Kelly, S.J., Scarlett, E.L., Rehing, C.D., Huang, W., Hershfield, M.S. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56(3): 1021-8.
54. An, Q., Lei, Y., Jia, N. et al. Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics. Biomolec Engineer 2007, 24: 643-9.
55. Walsh, S., Shah, A., Mond, J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 2003, 47(2): 554-8.
56. Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S., Asano, K. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res 1991, 51(14): 3710-4.
57. Tsutsumi, Y., Kihira, T., Tsunoda, S. et al. Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity. J Control Release 1995, 33: 447-51.
58. Shibata, H., Yoshioka, Y., Ikemizu, S. et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004, 10(24): 8293-300.
59. Youn, Y.S., Jung, J.Y., Oh, S.H., Yoo, S.D., Lee, K.C. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 2006, 114(3): 334-42.
60. Youn, Y.S., Jeon, J.E., Chae, S.Y., Lee, S., Lee, K.C. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagons-like peptide-1 in type 2 diabetic db/db mice. Diabetes Obes Metab 2008, 10(4): 343-6.
61. Cox, G.N., Rosendahl, M.S., Chlipala, E.A., Smith, D.J., Carlson, S.J., Doherty, D.H.A. Long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. Endocrinology 2007, 148(4): 1590-7.
62. Chapman, A.P. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002, 54(4): 531-45.